Iomab-ACT: A Pilot Study of 131-I Apamistamab (Iomab-B) Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Conditions:   B-ALL;   DLBCL;   B ALL;   Dlbcl-Ci;   DLBCL Unclassifiable;   DLBCL, Nos Genetic Subtypes;   DLBCL Activated B-Cell Type;   DLBCL Germinal Center B-Cell Type;   Diffuse Large B-cell Lymphoma;   HGBL;   HGBL, Nos Interventions:   Drug: 131-I Apamistamab;   Biological: CAR T-cell Sponsors:   Memorial Sloan Kettering Cancer Center;   Actinium Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials